ロード中...
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
Treatment options for patients with heavily pretreated relapsed and/or refractory multiple myeloma remain limited. We evaluated a novel therapeutic regimen consisting of carfilzomib, pomalidomide, and dexamethasone (CPD) in an open-label, multicenter, phase 1, dose-escalation study. Patients who rel...
保存先:
| 出版年: | Blood |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4643003/ https://ncbi.nlm.nih.gov/pubmed/26384354 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-05-643320 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|